north bergen,new jersey 4/1/2010 1:02:59 AM
News / Business

Breakthrough Stock, Pressure BioSciences Inc’s hits Wall Street with Latest Announcement.

Pressure BioSciences Inc Releases Fourth Quarter Earnings Today.

Pressure BioSciences, Inc. (NASDAQ:PBIO) today announced strong financial results for the 2009 fourth quarter. Pressure BioSciences Inc trades on the “NASDAQ” under the stock symbols “PBIO”. For More information regarding “PBIO”, make sure to visit the Most Exclusive and In Depth newsletter website at: http://www.wallstreetgrand.com/.

 

 

Join today and be part of the best free investment newsletter on the web where we focus on market moving news.

 

Pressure BioSciences, Inc. (NASDAQ:PBIO) today announced strong financial results for the 2009 fourth quarter.

 

Total revenue for the 2009 fourth quarter was $350,340 compared to $334,041 for the comparable period in 2008. Revenue from the sale of PCT products and services was $245,674 for the three months ended December 31, 2009 compared to $233,256 for the same period in 2008. During the 2009 fourth quarter, the Company completed the installation of twelve Barocycler instruments, compared to ten during the same period of 2008. Operating loss for the fourth quarter of 2009 was $777,144 compared to $900,100 for the same period in 2008. After the exclusion of non-cash charges, cash burn for the 2009 fourth quarter was approximately $622,000, compared to approximately $800,000 for the fourth quarter of 2008, a decrease of 22%.

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 US and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

 

 

 

You can contact us during market hours at 1-888-9-ClubGrand (1888-925-8247) or via email at staff@wallstreetgrand.com.

 

 

 

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") including 2009 growth, revenue for the second quarter and year of 2009 and gross margin for the second quarter and year of 2009. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the impact of intense competition, the continuation or worsening of current economic conditions and the condition of the domestic and global credit and capital markets.

 

Disclaimer:

 

Wall Street Grand LLC has not been compensated by the company for this press release and does not expect to be compensated in the future for any type of awareness. To read our full disclaimer clicks the link http://www.wallstreetgrand.com/disclosure.html